Surgery Partners, Inc. insider trading
Every open-market purchase and sale by Surgery Partners, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Surgery Partners, Inc.’s insiders pay?
From October 23, 2015 to August 19, 2026, 25 insiders reported 6 open-market purchases and 127 sales not made under a pre-set plan in Surgery Partners, Inc. Twelve months after each purchase was reported, the shares were +64.3% against the S&P 500 on average (median +2.7%), over 5 purchases with a full year of prices; 80% beat the index. After sales, the shares moved −32.4% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 22, 2019 into $76,484 by November 2, 2026, +32.8% a year. It held shares 39% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $16,218 (+7.0% a year), and held throughout $28,729 (+15.8%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Doherty David T | Chief Financial Officer | 0 | — | — | 18 | −39.2% (16) | March 16, 2026 |
| Baldock Jennifer | Chief Admin & Dev Officer | 0 | — | — | 16 | −40.7% (14) | March 16, 2026 |
| Evans Jason Eric | Chief Executive Officer | 1 | +165.8% (1) | 100% | 15 | −38.7% (13) | March 16, 2026 |
| Deluca Teresa | Director | 3 | −6.4% (2) | 50% | 8 | +11.7% (8) | August 19, 2026 |
| Owens Bradley R. | National Group President | 0 | — | — | 11 | −36.0% (11) | June 3, 2024 |
| Taparo Anthony | Chief Growth Officer | 0 | — | — | 11 | −31.5% (11) | March 13, 2024 |
| Brittenham Marissa | Chief Strategy Officer | 0 | — | — | 7 | −44.0% (5) | March 16, 2026 |
| Burkhalter Danielle | Chief Human Resources Officer | 0 | — | — | 7 | −42.8% (5) | March 16, 2026 |
| Goodwin George | American Group President | 0 | — | — | 7 | −22.9% (7) | June 8, 2022 |
| Bane Harrison R. | National Group President | 0 | — | — | 6 | −48.2% (6) | September 8, 2025 |
| Brocklehurst Laura L. | Chief Human Resources Officer | 0 | — | — | 4 | −25.6% (4) | November 14, 2022 |
| Deveydt Wayne S | Exec Chairman of the Board | 0 | — | — | 3 | −41.2% (3) | December 21, 2023 |
| Cowhey Thomas F. | Chief Financial Officer | 1 | +165.8% (1) | 100% | 1 | −2.9% (1) | May 7, 2021 |
| Mnaymneh Sami | 10% owner | 0 | — | — | 2 | +16.8% (2) | September 5, 2017 |
| Webb William Trenton | American Group President | 0 | — | — | 2 | −67.0% (1) | March 9, 2026 |
| Bcpe Seminole Holdings II Intermediate LP | Director | 0 | — | — | 1 | −63.4% (1) | December 21, 2023 |
| Deane John A | Director | 0 | — | — | 1 | +91.3% (1) | September 21, 2020 |
| Doyle Michael Thomas | Chief Executive Officer | 0 | — | — | 1 | +1.8% (1) | October 23, 2015 |
| Feinstein Adam T | Director | 0 | — | — | 1 | +22.2% (1) | May 20, 2019 |
| Hendrix Blair E | Director | 0 | — | — | 1 | −63.4% (1) | December 21, 2023 |
| Kaplan Andrew T. | Director | 0 | — | — | 1 | −63.4% (1) | December 21, 2023 |
| Lingle Brandan | Pres., Ancillary Svces. Grp. | 0 | — | — | 1 | −66.3% (1) | August 29, 2018 |
| Maryland Patricia Anne | Director | 0 | — | — | 1 | −57.3% (1) | August 13, 2025 |
| O'reilly T. Devin | Director | 0 | — | — | 1 | −63.4% (1) | December 21, 2023 |
| Turner Brent | Director | 1 | +2.7% (1) | 100% | 0 | — | November 22, 2022 |
When several insiders traded Surgery Partners, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Surgery Partners, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged +80.1% against the index. After 7 selling crowds, −26.5%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 31, 2026 | 6 selling | +24.3% | −1.5% | not yet |
| August 29, 2025 | 3 selling | −31.0% | −44.7% | −55.1% |
| February 28, 2025 | 5 selling | −1.4% | −15.0% | −58.0% |
| December 29, 2023 | 6 selling | −21.9% | −42.1% | −58.7% |
| February 28, 2023 | 6 selling | +2.6% | −9.5% | −37.4% |
| November 30, 2022 | 2 buying | +20.4% | +34.7% | +5.9% |
| March 31, 2022 | 9 selling | −28.0% | −37.2% | −29.8% |
| May 28, 2021 | 4 selling | −25.8% | −35.2% | −31.4% |
| August 30, 2019 | 2 buying | +106.0% | +125.4% | +174.6% |